Ashleigh Burdette, MSN, RN, Sr. Director, Clinical Innovation at Biologics By McKesson explains that though personalized care is typically essential for cancer patients, it’s even more so in a COVID-19 and post-COVID landscape. Cancer patients are among some of the most at risk for contracting COVID-19 and with diminished immune systems, can experience worse symptoms. She talks about how personalized care plans for oncology patients allow for easier connection to therapies via McKesson’s network of payers, providers, and pharmacies.
Ashleigh has been a Registered Nurse for over 13 years and holds a Master of Science in Nursing with a specialization in leadership and administration. She began her nursing career as an oncology nurse working in both bone marrow transplant and an outpatient clinic. In 2015, she joined Optum/United Health Group to focus on oncology patient support, utilization review, and clinical case management. In 2017, she joined Cardinal Health’s hub business and had the opportunity to lead both clinical operations and account management. Ashleigh joined Biologics by McKesson in 2020 to lead cross-functional collaboration to create customized patient management solutions that support the holistic needs of patients.